This site is intended for health professionals only

Published on 3 June 2010

Share this story:
Twitter
LinkedIn

Shire files suit against Anchen Pharmaceuticals, Inc. and Anchen, Inc.

teaser

Shire plc, the global specialty biopharmaceutical company, announces that its subsidiary Shire LLC has filed a lawsuit in the U.S. District Court for the District of Delaware against Anchen Pharmaceuticals, Inc. and Anchen, Inc. (collectively “Anchen”) for the infringement of U.S. Patent Nos. 5,854,290 (the ‘290 patent), 6,287,599 (the ‘599 patent), and 6,811,794 (the ‘794 patent).

The lawsuit results from an Abbreviated New Drug Application (ANDA) filed by Anchen for generic versions of 1 mg, 2 mg, 3 mg and 4 mg guanfacine hydrochloride extended release tablets, INTUNIV(TM), which seeks to market such generic products before the expiration of the ‘290, ‘599, and ‘794 patents. The regulatory exclusivity period for INTUNIV(TM) runs through September 2, 2012.

For more information, please click the link below:
Shire

 



Most read



Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn